Avilés A, Díaz-Maqueo J C, García E L, Talavera A, Guzmán R
Department of Hematology, Oncology Hospital, National Medical Center, IMSS, México, D.F.
Invest New Drugs. 1992 Nov;10(4):351-5. doi: 10.1007/BF00944195.
Forty-eight consecutive patients with diffuse large cell lymphoma (DLCL) in complete remission (CR) after conventional chemotherapy were enrolled in a prospective clinical trial. The maintenance therapy was a random either nothing or interferon alfa 2b (IFN) 5.0 MU three times a week for one year. The median duration of CR in the patients treated with IFN has not been reached. After five years 60% of patients remain in CR compared to the control group who had a median CR of 40 months (p < 0.001). Actuarial five-years survival in the IFN treated patients was 88% compared to 42% in the control group (p < 0.001). Maintenance therapy with IFN has been beneficial in patients with DLCL with improvement of duration of CR and survival without the excessive toxicity of most common third generation regimen chemotherapy. We felt that IFN could be explored in most controlled clinical trials in patients with DLCL in CR after conventional chemotherapy.
48例经传统化疗后处于完全缓解（CR）状态的弥漫性大细胞淋巴瘤（DLCL）患者被纳入一项前瞻性临床试验。维持治疗被随机分为两组，一组不进行任何治疗，另一组接受干扰素α-2b（IFN）5.0 MU，每周三次，持续一年。接受IFN治疗的患者的CR中位持续时间尚未达到。五年后，60%的患者仍处于CR状态，而对照组的CR中位时间为40个月（p < 0.001）。接受IFN治疗的患者的精算五年生存率为88%，而对照组为42%（p < 0.001）。IFN维持治疗对DLCL患者有益，可改善CR持续时间和生存率，且没有大多数常见第三代方案化疗的过度毒性。我们认为，在大多数对照临床试验中，可以对经传统化疗后处于CR状态的DLCL患者探索使用IFN。
